Drug intelligence / Profile preview

dicyclol

Development stage: Unknown
Lead developer: Renji Hospital
Administration: Oral

Overview

Dicyclol is a drug currently undergoing a Phase III clinical trial for the treatment of acute drug-induced liver injury (DILI). The intervention in the trial is described as Dicyclic alcohol (25 mg/tablet). Beyond its investigation for DILI, specific details regarding its mechanism of action, chemical structure, or developer are not readily available in public databases, and it should not be confused with Dicyclomine, an anticholinergic agent used for gastrointestinal disorders, which has not been linked to liver injury.

Other names: Dicyclic alcohol

Targets

M1 (Muscarinic acetylcholine receptor M1)CHRM3 (M3)CHRM2 (M2)H (Histamine receptors)Bradykinin B2 receptor

Beyond the preview

Go deeper on dicyclol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on dicyclol.

Explore the full profile